Development and Validation of a Multivariate Prediction Model of Perioperative Mortality in Neurosurgery: The New Zealand Neurosurgical Risk Tool (NZRISK-NEURO).

BACKGROUND: Multivariate risk prediction models individualize prediction of adverse outcomes, assisting perioperative decision-making. There are currently no models specifically designed for the neurosurgical population. OBJECTIVE: To develop and validate a neurosurgical risk prediction model, with 30-d, 1-yr, and 2-yr mortality endpoints. METHODS: We accessed information on all adults in New Zealand who underwent neurosurgery or spinal surgery between July 1, 2011, and June 30, 2016, from an administrative database. Our dataset comprised of 18 375 participants, split randomly into derivation (75%) and validation (25%) datasets. Previously established covariates tested included American Society of Anesthesiologists physical status grade (ASA-PS), surgical acuity, operative severity, cancer status, and age. Exploratory covariates included anatomical site, gender, diabetes, trauma, ethnicity, and socioeconomic status. Least absolute shrinkage and selection operator (LASSO) regression analysis was used to construct 30-d, 1-yr, and 2-yr mortality models. RESULTS: Our final models included 8 covariates: age, ASA-PS grade, surgical acuity, cancer status, anatomical site, diabetes, ethnicity, and trauma. The area under the receiver operating curve for the 30-d, 1-yr, and 2-yr mortality models was 0.90, 0.91, and 0.91 indicating excellent discrimination, respectively. Calibration also showed excellent performance with McFadden's pseudo R2 statistics of 0.28, 0.37, and 0.41 and calibration plot slopes of 0.93, 0.95, and 0.94, respectively. The strongest predictors of mortality were ASA-PS 4 and 5 (30 d) and cancer (1 and 2 yr). CONCLUSION: NZRISK-NEURO is a robust multivariate calculator created specifically for neurosurgery, enabling physicians to generate data-driven individualized risk estimates, assisting shared decision-making and perioperative planning.

Pullout force of minimally invasive surgical and open pedicle screws-a biomechanical cadaveric study.

BACKGROUND: To assess whether lumbar pedicle screw placement with a minimally invasive surgical (MIS) vs. open technique imparts different biomechanical parameters and thus may affect failure rates. METHODS: Human cadaveric disarticulated lumbar vertebrae 1-5 were stabilised in cement. Pedicle screws were inserted either via the 'MIS' or 'open' technique, based on previously described anatomical landmarks. Each vertebra had one 'MIS' and one 'open' technique screw. Specimens were tested with an Instron mechanical testing machine, positioned to allow for testing of direct coaxial force. Load was applied until failure occurred, and load-displacement curves generated for each screw. RESULTS: Average failure load was found to be 685±399 N for MIS, versus 661±323 N for open technique (P=0.75). The average ultimate failure load was 748±421 N for MIS, versus 772±326 N for open (P=0.74). Average displacement until failure was 0.95±0.49 mm for MIS as compared to 0.95±0.62 mm for open (P=0.996). Axial stiffness was 936±217 N/mm for MIS and 1,016±263 N/mm for open (P=0.19). Average work required to result in failure was 0.84±1.09 J for MIS and 0.82±1.05 J for open (P=0.94). CONCLUSIONS: There was no significant difference in the biomechanical properties of the MIS as compared with open lumbar pedicle screws, when tested until failure under direct coaxial force. The clinical implication may be that there is no significant advantage in the biomechanical properties of MIS versus open lumbar pedicle screw insertion techniques.

Pedicle length and degree of slip in lumbosacral isthmic spondylolisthesis.

OBJECTIVE: The present retrospective study was performed to assess the anatomical features of the pedicle in isthmic spondylolisthesis and to correlate this with degree of slip. METHODS: Twenty-six patients with isthmic spondylolytic spondylolisthesis were studied. Relevant patient variables, length, width, height of the L5 pedicle, and the product of height and angle between pedicle and vertebral midline were measured. The length of the posterior compartment of the pedicle was calculated as the product of the pedicle length and angle. RESULTS: With measurements comparable to those reported in previous publications, the L5 pedicle was found to be longer, and the height and width of the body shorter, than published values for patients without spondylolysis. The difference between the length of the posterior compartment of the pedicle and height of body is significantly proportional to the degree of slip and may reflect an adaptive response for stabilizing the vertebral body with posterior elements. CONCLUSIONS: The pedicle anatomy was found to be altered in patients with L5 S1 spondylolytic spondylolisthesis. These anatomical changes have implications for surgeons performing fusion operations in terms of length of screw, landmarks used and entry approach.

Systematic review of trimodality therapy for patients with malignant pleural mesothelioma.

BACKGROUND: Malignant pleural mesothelioma (MPM) is an aggressive form of cancer arising from the pleural mesothelium. Trimodality therapy (TMT) involving extrapleural pneumonectomy with neoadjuvant or adjuvant chemotherapy and adjuvant radiotherapy is a recognized treatment option with a curative intent. Despite encouraging results from institutional studies, TMT in the treatment of MPM remains controversial. The present systematic review aims to assess the safety and efficacy of TMT in the current literature. METHODS: A systematic review was performed using five electronic databases from 1 January 1985 to 1 October 2012. Studies were selected independently by two reviewers according to predefined selection criteria. The primary endpoint was overall survival. Secondary endpoints included disease-free survival, disease recurrence, perioperative morbidity and length of stay. RESULTS: Sixteen studies were included for quantitative assessment, including one randomized controlled trial and five prospective series. Median overall survival ranged from 12.8-46.9 months. Disease-free survival ranged from 10-16.3 months. Perioperative mortality ranged from 0-12.5%. Overall perioperative morbidity ranged from 50-82.6% and the average length of stay was 9-14 days. CONCLUSIONS: Outcomes of patients who underwent TMT in the current literature appeared to be inconsistent. Four prospective series involving a standardised treatment regimen with neoadjuvant chemotherapy indicated encouraging results based on intention-to-treat analysis. However, a small study assessing the feasibility of conducting a randomized controlled trial for TMT versus conservative treatment reported poor short- and long-term outcomes for patients who underwent pneumonectomy. Overall, results of the present systematic review suggest TMT may offer acceptable perioperative outcomes and long-term survival in selected patients treated in specialized centers.

Mesenchymal stem cell conditioned media attenuates in vitro and ex vivo myocardial reperfusion injury.

BACKGROUND: Previous studies have suggested that implantation of mesenchymal stem cells (MSC) or their conditioned media (MSC CM) improves heart function after myocardial infarction. We sought to determine whether MSC and MSC CM added at the onset of reperfusion attenuates myocardial reperfusion injury. METHODS: Rat MSC and neonatal rat cardiomyocytes (NRC) were isolated and cultured separately. NRC were subjected to simulated in vitro ischemia/reperfusion (I/R). At the onset of reperfusion, NRC received either fresh medium (control group) or one of the following treatments: MSC in fresh medium; MSC CM alone (without MSC); MSC CM + inhibitors of PI3K (LY294002 or Wortmannin); MSC CM + antibodies neutralizing IGF-1 or VEGF; MSC + inhibitors of PI3K; or cyclosporine. Cell injury was assessed by LDH activity and MTT staining at the end of reperfusion. VEGF, IGF-1 and HGF were measured in each experimental treatment preparation. Ex vivo experimentation on isolated rat hearts subjected to I/R were performed to evaluate the protective effects of MSC CM on myocardial reperfusion injuries measured through CK release and infarct size after TTC staining. RESULTS: In vitro cell injury was significantly reduced by MSC, MSC CM and CsA. PI3K inhibitors significantly attenuated the protection afforded by MSC CM but not growth factor inhibitors. Ex vivo experimentation showed that MSC CM significantly reduced myocardial I/R injury. CONCLUSION: Our data suggest that MSC CM added at the onset of reperfusion can protect myocardium from I/R injury. In vitro data suggest a protection mediated by paracrine activation of the PI3K pathway.